Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2001

View Archived Issues

Beta-amyloid peptide causes cognitive loss in AD via nicotinic receptor block

Id4 identified as regulator of BRCA1 expression

Novel cell-based transplantation therapy investigated for MS

NS-7 for both acute and chronic sequelae of cerebral ischemia

Initial results from pivotal trial of Cubist's Cidecin announced

Merck's second-generation HRT patch receives positive opinion in E.U.

Thrombin inhibition with PEG-hirudin as a new approach to the therapy of arthritis

XTL purchases stake in iviGene, gains access to technology

New safety information for miconazole vaginal cream and suppositories mandated by FDA

Beneficial effects of simvastatin independent of its cholesterol-lowering action

Argatroban enters phase II for ischemic stroke

XV-454 compares favorably to abciximab in flow models of thrombosis in vitro

Marketing application filed in Australia for PhotoCure's Metvix PDT

E.C. approves Rapamune for immunosuppression following renal transplantation

Bioenvision announces codevelopment partner for clofarabine

Pneumococcal vaccines claimed by Erasmus University

Modified erythropoietin with increased biological activity

Chymase-inhibitory thiazine and pyrazine derivatives under study at Santen

Potent and selective 5-ht6 receptor antagonists and their use described by NPS Allelix

Sumitomo presents new agents for immune and inflammatory disorders

Somatostatin receptor modulators designed at SCRAS

Draximage obtains license to infection imaging agent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...